301093.SHE Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
- Market cap
- CNY 9.90B
- P/E
- 257.9x
- P/B
- 4.49x
- ROE
- 1.9%
- Dividend yield
- 0.26%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301093.SHE undervalued?
Graham numberThe Graham number of Jiangsu Hualan New Pharmaceutical Material Co. Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. fundamental analysis
No fundamental analysis for Jiangsu Hualan New Pharmaceutical Material Co. Ltd. yet.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. engages in the research and development, manufacture, and sale of packaging materials for the injectable pharmaceuticals in China and internationally. It offers laminated and conventional rubber stoppers; halogenated butyl polytetrafluoroethylene film rubber stoppers and halogenated butyl polyester film rubber stoppers; and rubber components for pen syringes (cassette vials), assemblies for plastic infusion containers, sili…
Full company profileJiangsu Hualan New Pharmaceutical Material Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 460M | 446M | 821M | 584M | 623M | 586M | 619M | 614M |
| Gross Profit | 238M | 209M | 452M | 255M | 259M | 227M | 241M | 255M |
| Operating Income | 125M | 105M | 261M | 73.6M | 85.9M | 40.6M | 57.5M | 46.6M |
| EBITDA | 215M | 128M | 286M | 145M | 182M | 115M | 138M | 49.7M |
| Net Income | 95.2M | 81.4M | 216M | 93.8M | 118M | 49.6M | 60.2M | 42.9M |
| EPS | 0.94 | 0.81 | 1.23 | 0.41 | 0.51 | 0.39 | 0.37 | 0.20 |
| Balance Sheet | ||||||||
| Total Assets | 598M | 622M | 2.63B | 2.58B | 2.71B | 2.50B | 2.55B | 2.64B |
| Total Liabilities | 237M | 225M | 217M | 164M | 225M | 256M | 355M | 436M |
| Shareholders' Equity | 360M | 396M | 2.42B | 2.42B | 2.49B | 2.25B | 2.19B | 2.21B |
| Cash & Short-term Investments | 48.3M | 58.5M | 1.87B | 146M | 422M | 400M | 354M | 234M |
| Cash Flow | ||||||||
| Operating Cash Flow | 92.1M | 133M | 217M | 94.9M | 224M | 121M | 115M | - |
| Capital Expenditure | 29.8M | 39.5M | 124M | 174M | 297M | 135M | 133M | 92.0M |
| Free Cash Flow | 62.3M | 93.9M | 92.8M | -78.7M | -73.4M | -14.6M | -17.1M | 48.7M |
| Ratios | ||||||||
| ROE | 26.4% | 20.5% | 8.9% | 3.9% | 4.7% | 2.2% | 2.7% | 1.9% |
| ROA | 15.9% | 13.1% | 8.2% | 3.6% | 4.3% | 2.0% | 2.4% | 1.6% |
| Net Profit Margin | 20.7% | 18.2% | 26.3% | 16.0% | 18.9% | 8.5% | 9.7% | 7.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. dividends
- Dividend yield
- 0.26%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 43.5%
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 26.2M | 0.16 | 43.5% |
| 2024 | CNY 77.7M | 0.61 | 156.6% |
| 2023 | CNY 40.9M | 0.18 | 34.7% |
| 2022 | CNY 94.9M | 0.42 | 101.2% |
| 2021 | CNY 4.47M | 0.03 | 2.1% |
| 2020 | CNY 52.0M | 0.51 | 63.9% |
| 2019 | CNY 53.3M | 0.53 | 56.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jul 16, 2026.
Who owns Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
- Insiders 36.41%
- Institutions 18.64%
- Public & others 44.94%
- Shares outstanding 213M
- Free float 144M
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. company profile
- Company name
- Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
- Ticker
- 301093.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 945
- Fiscal year end
- December
- Address
- No. 1488, Chenglu, Jiangyin, China, 214443
- Phone
- 86 51 0689 78889
- Website
- hua-lan.com
About Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. engages in the research and development, manufacture, and sale of packaging materials for the injectable pharmaceuticals in China and internationally. It offers laminated and conventional rubber stoppers; halogenated butyl polytetrafluoroethylene film rubber stoppers and halogenated butyl polyester film rubber stoppers; and rubber components for pen syringes (cassette vials), assemblies for plastic infusion containers, silicone rubber products, medical devices and accessories, etc. Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. was founded in 1992 and is based in Jiangyin, China.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. management
6- Mr. Yimin HuaGM & Chairman · born 1982
- Mr. Lizhong XuFinancial Director & Deputy GM · born 1973
- Mr. Feng XiaoDeputy GM & Director · born 1963
- Ms. Xue LiuDeputy GM & Secretary of the Board · born 1995
- Mr. Zhimin HuaDeputy General Manager · born 1989
- Mr. Wuping WangAccounting Supervisor